Microbiotix is a privately-held, clinical stage biopharmaceutical company engaged in the discovery and development of novel small molecule anti-infective drugs. The Company’s clinical programs are focused on hepatitis C virus (HCV) and cytomegalovirus (CMV).
Location: United States, Massachusetts, Worcester
Employees: 11-50
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | CARB-X | carb-x.org |
Mentions in press and media 3
| Date | Title | Description |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| 09.08.2007 | More Government Dollars for Alnylam Biodefense Initiative | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Cambridge-based Alnylam Pharmaceuticals (NASDAQ:ALNY) announced today that it has been awarded a three-year, $39 million contract with the U.S. Defense Threat Reduction Agency... |
| - | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain. The international antimicrobial consortium today announced grants totaling $48 million, spread across 11 companies in the U.S. and U.K. Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteri... |